Enis Aboalhasan

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

Obesity (Silver Spring, Md.)

Postgraduate medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis. Obesity (Silver Spring, Md.) 31 (6) (2023)
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes, obesity & metabolism 25 (4) (2022)
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes, obesity & metabolism (2022)
Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri, Ronen Arbel
Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate medicine 134 (7) (2022)
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes, obesity & metabolism 25 (4) (2022)
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes, obesity & metabolism 25 (4) (2022)